

## Refine Search

### Search Results -

Terms	Documents
L3 and fiv	4

**Database:**

- US Pre-Grant Publication Full-Text Database
- US Patents Full-Text Database
- US OCR Full-Text Database
- EPO Abstracts Database
- JPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

**Search:**

L7

Refine Search

Recall Text

Clear

Interrupt

### Search History

**DATE:** Sunday, October 30, 2005 [Printable Copy](#) [Create Case](#)

Set	Name	Query	Hit	Set
			Count	Name
side by side				result set
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR				
<u>L7</u>	<u>L3</u> and fiv		4	<u>L7</u>
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR				
<u>L6</u>	<u>L3</u> and therapeutic\$		13	<u>L6</u>
<u>L5</u>	<u>L3</u> and therpaetic\$		0	<u>L5</u>
<u>L4</u>	LCMV near10 (envelop\$ or glycoprotein\$) near20 inducib\$ near5 promoter\$		0	<u>L4</u>
<u>L3</u>	LCMV near10 (envelop\$ or glycoprotein\$) and inducib\$ near5 promoter\$		13	<u>L3</u>
<u>L2</u>	LCMV and inducib\$ near5 promoter\$		102	<u>L2</u>
<u>L1</u>	LCMV and inducib\$		142	<u>L1</u>

END OF SEARCH HISTORY

BEGIN 5,6,55,154,155,156,312,399,BIOTECH,BIOSCI

Set	Items	Description
		---
?		
S	(LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND PSEUDOTYP?	
>>>File 5 processing for VIR? stopped at VIROMAX		
>>>File 155 processing for VIR? stopped at VIRUMIN		
>>>File 73 processing for VIR? stopped at VIRUSTOMYCIN		
Processing		
Processed 10 of 39 files ...		
>>>File 144 processing for VIR? stopped at VIRTUOZO		
>>>File 50 processing for VIR? stopped at VIRUSVAKTSINOI		
Completed processing all files		
6497	LCMV	
283843	LYMPHOCYTIC	
16208	CHORIOMENINGITIS	
6354634	VIR?	
10155	LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?	
11588	PSEUDOTYP?	
S1	174 (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND PSEUDOTYP?	
?		
S	S1 AND (WE54 OR WE (N) 54 OR HP1 OR HPI)	
Processed 10 of 39 files ...		
Processing		
Completed processing all files		
174	S1	
58	WE54	
19101270	WE	
987561	54	
685	WE (N) 54	
5424	HP1	
5650	HPI	
S2	13 S1 AND (WE54 OR WE (N) 54 OR HP1 OR HPI)	
?		
RD S2		
>>>Duplicate detection is not supported for File 391.		
>>>Records from unsupported files will be retained in the RD set.		
...completed examining records		
S3	7 RD S2 (unique items)	
?		
Display 3/3/1 (Item 1 from file: 154)		
DIALOG(R)File 154: MEDLINE(R)		
(c) format only 2005 Dialog. All rts. reserv.		
18202725	PMID: 15727934	
The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain.		
Stein Colleen S; Martins Ines; Davidson Beverly L		
Program in Gene Therapy, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA 52242, USA.		
Molecular therapy - the journal of the American Society of Gene Therapy (United States) Mar 2005, 11 (3) p382-9, ISSN 1525-0016		
Journal Code: 100890581		
Contract/Grant No.: DK54759; DK; NIDDK; NS34568; NS; NINDS		
Publishing Model Print		

Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

- end of record -

?

**Display 3/3/2 (Item 1 from file: 399)**  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

**142476299 CA: 142(26)476299z PATENT**  
Methods for producing and using in vivo pseudotyped retroviruses using  
envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for  
human gene delivery  
INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609  
APPLICATION: US 2004993319 (20041119) \*US 2003718262 (20031120)  
PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO  
LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;  
C07K-014/005B; C12N-015/86B

- end of record -

?

**Display 3/3/3 (Item 2 from file: 399)**  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

**137016445 CA: 137(2)16445g JOURNAL**  
Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic  
choriomeningitis virus glycoprotein: generation, concentration, and broad  
host range  
AUTHOR(S): Beyer, Winfried R.; Westphal, Manfred; Ostertag, Wolfram; Von  
Laer, Dorothee  
LOCATION: Heinrich-Pette-Institut fur Experimentelle Virologie und  
Immunologie an der Universitat Hamburg, Hamburg, Germany, D-20251  
JOURNAL: J. Virol. (Journal of Virology) DATE: 2002 VOLUME: 76  
NUMBER: 3 PAGES: 1488-1495 CODEN: JOVIAM ISSN: 0022-538X LANGUAGE:  
English PUBLISHER: American Society for Microbiology

- end of record -

?

**Display 3/3/4 (Item 1 from file: 266)**  
DIALOG(R)File 266:FEDRIP  
Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00624119  
IDENTIFYING NO.: 2P01HL051670-11 0005 AGENCY CODE: CRISP  
**Targeting Entry in Epithelia with ICMV-FIV**  
PRINCIPAL INVESTIGATOR: MCCRAY, PAUL B, JR  
ADDRESS: PAUL-MCCRAY@UIOWA.EDU UNIVERSITY OF IOWA 616 MEDICAL RESEARCH  
CENTER IOWA CITY, IA 52242  
PERFORMING ORG.: UNIVERSITY OF IOWA, IOWA CITY, IOWA  
SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE  
DATES: 2009/01/97 TO 2003/31/09 FY : 2004

- end of record -

?

Display 3/3/5 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0372996 DBR Accession No.: 2005-18702 PATENT

Transducing a nervous system cell with a transgene comprises contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene - virus vector expression in host cell for use in disease therapy and gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L; STEIN C

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L; STEIN C 2005

PATENT NUMBER: US 20050123517 PATENT DATE: 20050609 WPI ACCESSION NO.: 2005-416924 (200542)

PRIORITY APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

NATIONAL APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

LANGUAGE: English

- end of record -

?

Display 3/3/6 (Item 2 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT

New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005

PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.: 2005-371617 (200538)

PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

LANGUAGE: English

- end of record -

?

Display 3/3/7 (Item 3 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0329671 DBR Accession No.: 2004-01963 PATENT

New chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a heterologous amino acid sequence, useful for inducing an immune response against Ebola virus, bacteria, or fungi - involving vector-mediated gene transfer and expression in host cell for use in therapy

AUTHOR: WILSON J M; MEDINA M F C; KOBINGER G

PATENT ASSIGNEE: UNIV PENNSYLVANIA 2003

PATENT NUMBER: WO 200392582 PATENT DATE: 20031113 WPI ACCESSION NO.: 2004-011795 (200401)

PRIORITY APPLIC. NO.: US 427752 APPLIC. DATE: 20021120  
NATIONAL APPLIC. NO.: WO 2003US11494 APPLIC. DATE: 20030428  
LANGUAGE: English

- end of record -

?

Display 3/9/7 (Item 3 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0329671 DBR Accession No.: 2004-01963 PATENT

New chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a heterologous amino acid sequence, useful for inducing an immune response against Ebola virus, bacteria, or fungi - involving vector-mediated gene transfer and expression in host cell for use in therapy

AUTHOR: WILSON J M; MEDINA M F C; KOBINGER G

PATENT ASSIGNEE: UNIV PENNSYLVANIA 2003

PATENT NUMBER: WO 200392582 PATENT DATE: 20031113 WPI ACCESSION NO.: 2004-011795 (200401)

PRIORITY APPLIC. NO.: US 427752 APPLIC. DATE: 20021120

NATIONAL APPLIC. NO.: WO 2003US11494 APPLIC. DATE: 20030428

LANGUAGE: English

ABSTRACT: DERWENT ABSTRACT: NOVELTY - A chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a

-more-

?

Display 3/9/7 (Item 3 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

heterologous amino acid sequence, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a nucleic acid molecule encoding a chimeric Ebola protein defined above; (2) a host cell comprising the chimeric Ebola protein or nucleic acid molecule encoding the protein; (3) a method of inducing an immune response against Ebola by delivering a composition comprising the chimeric Ebola protein or nucleic acid molecule encoding the protein; (4) a recombinant virus having a chimeric Ebola envelope protein and a minigene; (5) a host cell containing the recombinant virus; (6) a method of treating a patient with a selected molecule by transducing the cells of the patient with the recombinant virus above; (7) a method of delivering a molecule to the apical cells of the lung by administering a recombinant virus above intratracheally; (8) an immunogenic composition comprising a DNA molecule encoding a chimeric Ebola envelope protein above under the control of sequences which direct its expression in a host cell, and a carrier; and (9) an

-more-

?

Display 3/9/7 (Item 3 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

immunogenic composition comprising an Ebola envelope protein defined above, and a carrier. BIOTECHNOLOGY - Preferred Protein: The chimeric Ebola envelope protein contains a wild-type Ebola glycoprotein-binding domain. The heterologous amino acid sequence is an Ebola glycoprotein

sequence, which is non-contiguous with the binding domain in the wild-type Ebola. The chimeric Ebola envelope protein comprises an Ebola signal peptide and an Ebola binding domain having a deletion in the native Ebola region between the signal peptide and the binding domain, where the deletion is about 1-50 amino acids between the signal peptide and the binding domain. Alternatively, the chimeric Ebola envelope protein comprises a deletion of the complete Ebola signal peptide or its portion, where the deletion of all or a portion of the carboxy terminus of the signal peptide comprises a deletion of about 1-30 amino acids, or a deletion of all or a portion of the Ebola transmembrane consisting of a deletion of about 1-23 amino acids. The chimeric Ebola envelope protein may also comprise a deletion of all or a portion of

-more-

?

**Display 3/9/7 (Item 3 from file: 357)**

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

the Ebola cytoplasmic domain, which comprises a deletion of about 1-3 amino acids. The chimeric Ebola envelope protein comprises a transmembrane domain from a heterologous protein and a cytoplasmic domain, where the heterologous amino acid sequence from a non-Ebola protein. The heterologous amino acid sequence is selected from a Vesicular Stomatitis Virus protein, a human immunodeficiency virus transmembrane domain, a murine leukemia virus, and a Lymphocytic Choriomeningitis virus. The chimeric Ebola envelope protein is selected from: (a) NTDL1, amino acids 1-366 fused to amino acids 497 to 676 of the Ebola glycoprotein comprising a sequence of 676 amino acids (SEQ ID NO: 1); (b) NTDL2, amino acids 1-366 fused to amino acids 502-676 SEQ ID NO: 1; (c) NTDL3, amino acids 1-370 fused to amino acids 492-676 of SEQ ID NO: 1; (d) NTDL4, amino acids 1-311 fused to amino acids 497-676 SEQ ID NO: 1; (e) NTDL5, amino acids 1-287 fused to amino acids 497-676 of SEQ ID NO: 1; (f) NTDL6, amino acids 1-279 fused to amino acids 497-676 of SEQ ID NO: 1; (g) NTDL7, amino acids 1-267 fused to amino acids

-more-

?

**Display 3/9/7 (Item 3 from file: 357)**

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

497-676 SEQ ID NO: 1; (h) NTDL8, amino acids 1-258 fused to amino acids 497-676 SEQ ID NO: 1; (i) NTDL9, amino acids 1-232 fused to amino acids 497-676 of SEQ ID NO: 1; (j) NTDL10, amino acids 1-231 fused to amino acids 497-676 of SEQ ID NO: 1; (k) DELTAN, amino acids 1-31 fused to amino acids 172-676 of SEQ ID NO: 1; (l) EboDELTAS, amino acids 1-220 of the Ebola glycoprotein comprising a sequence of 364 amino acids (SEQ ID NO: 2); (m) EboDELTAS, amino acids 1-361 of SEQ ID NO: 2; (n) EboDELTAS, amino acids 1-628 of SEQ ID NO: 2; and (o) EboDELTAS, amino acids 1-311 fused to amino acids 497-664 of SEQ ID NO: 2; (p) VTC, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 463-511 of a sequence of 856 amino acids (SEQ ID NO: 3) given in the specification; (q) -2aa, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 465-511 of SEQ ID NO: 3; (r) +2aa, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 461-511 of SEQ ID NO: 3; (s) +16aa, amino acids 1-672 of SEQ ID NO: 1 fused amino acids 447-511 of SEQ ID NO: 3; (t) +23aa, amino acids 1 - 672 of SEQ ID NO: 1 fused to amino acids

-more-

?

**Display 3/9/7 (Item 3 from file: 357)**

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent &amp; ISI. All rts. reserv.

440-511 of SEQ ID NO: 3; (u) +42aa, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 421-511 of SEQ ID NO: 3; (v) V/C, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 483-511 of SEQ ID NO: 3; (w) V/2C, amino acids 1-676 of SEQ ID NO: 1 fused to amino acids 483-511 of SEQ ID NO: 3; (x) V/T, amino acids 1-650 of SEQ ID NO: 1 fused to amino acids 463-482 of SEQ D NO: 3; (y) DELTAInt, amino acids 1-629 of SEQ ID NO: 1 fused to amino acids sequences 463-511 of SEQ ID NO: 3; (z) DELTAImm, amino acids 1-563 of SEQ ID NO: 1 fused to amino acids 463-511 of SEQ ID NO: 3; (a) VE, amino acids 180-350 of SEQ ID NO: 1 in the VS-G envelope, SEQ ID NO: 3; (b) H/TC, amino acids 1-650 of SEQ ID NO: 1 fused to amino acids 661-856 of a sequence of 856 amino acids (SEQ ID NO: 8); (c) M/C, amino acids 1-650 of SEQ ID NO: 1 fused to a VSV-G transmembrane domain, 465-482 of SEQ D NO: 3, and an MLV-GP cytoplasmic domain, amino acids 634-649 of a 654-amino acid sequence (SEQ ID NO: 6); (d) M/CR, amino acids 1-650 of SEQ ID NO: 1 fused to a VSV-G transmembrane domain, 465-482 of SEQ ID NO: 3, an MLV-GP

-more-

?

**Display 3/9/7 (Item 3 from file: 357)**

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent &amp; ISI. All rts. reserv.

cytoplasmic domain, amino acids 634-649 of SEQ ID NO: 6, and an R peptide of MLV-GP, amino acids 650-665 of MLV-GP, SEQ D NO: 6; and (e) L/TC, amino acids 1-650 of SEQ D NO: 1 fused to amino acids 439-498 of LCMV-GP comprising a sequence of 498 amino acids (SEQ ID NO: 9). Preferred Nucleic Acid: The nucleic acid molecule is a plasmid, a viral vector, or an adenoviral vector. Preferred Method: In inducing an immune response against Ebola, the composition is delivered intramuscularly or orally. In treating a patient with a selected molecule, the cells transduced are lung cells, dendritic cells and macrophages. The recombinant virus is administered directly to the patient. The transgene is a CFTR gene and the recombinant virus is administered intratracheally. The cells of the patient are transduced ex vivo, and are re-infuses into the patient having cancer. Preferred Virus: The minigene is a lentivirus minigene comprising Rev response element (RRE) sequences, where the lentivirus sequences are selected from human immunodeficiency virus (HIV) vector, simian immunodeficiency

-more-

?

**Display 3/9/7 (Item 3 from file: 357)**

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent &amp; ISI. All rts. reserv.

virus (SIV) vector, caprine arthritis and encephalitis virus, equine infectious anemia virus, visna virus, and feline immunodeficiency virus (FIV) vector, preferably an HIV. The 5' and 3' LTR sequences are self-reactivating, and contain a deletion in the U3 region. Preferred Composition: The immunogenic composition comprises a recombinant virus comprising the DNA molecule or a wild-type Ebola G or S protein. ACTIVITY - Virucide; Antibacterial; Antiparasitic; Cytostatic. MECHANISM OF ACTION - Vaccine. The cellular immune response to Ebola envelope in C57BL/6 mice was evaluated 8 days after a single

intramuscular administration of 581010 particles of C7-LacZ or C7-Ebola envelope variant per animal. Mice were vaccinated with 5x1010 particles of C7 encoding LacZ or Ebola envelope variant. Splenic lymphocytes from immunized mice were collected 8 days post vaccination, and stimulated in vitro with feeder cells. standard 5-hour CTL assays were performed sing 51Cr-labeled syngeneic C57 cells transfected with an expressor of EboZ. A positive MHC-restricted cytotoxic T lymphocyte response was

-more-

?

**Display 3/9/7 (Item 3 from file: 357)**

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

observed from all AdPan-7 encoding for Ebola envelope variants with a higher response from NTDL2, NTDL3 or NTDL4 immunized mice. Effector cells from C7 encoding Ebola envelope variant immunized mice recognized EboZ transfected target cells and gave recall CTL responses up to 30% specific lysis. Less than 5% lysis was seen with effector cells from naive or LacZ immunized control mice confirming that lysis was specific for Ebola envelope antigens. USE - The recombinant virus is useful in preparing a medicament (claimed). The chimeric Ebola envelope protein is useful as an antigen for inducing an immune response against Ebola virus, and for generating a chimeric Ebola-pseudotyped virus, which delivers a selected molecule to a target cell. The proteins may be used to provide heterologous envelope to any vector derived from a viral source, which natively contain has an envelope. The protein may further be used to immunize a (non-)human animal against other pathogens including bacteria, fungi, parasitic microorganisms or multicellular parasites, which infect human and non-human vertebrates, or from a

-more-

?

S (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND (RESIDUE (3N) 153 OR POSIT

>>>File 5 processing for VIR? stopped at VIROMAX

>>>File 155 processing for VIR? stopped at VIRUMIN

>>>File 73 processing for VIR? stopped at VIRUSTOMYCIN

Processing

Processed 10 of 39 files ...

>>>File 144 processing for VIR? stopped at VIRTUOZO

>>>File 50 processing for VIR? stopped at VIRUSVAKTSINOI

Completed processing all files

6497 LCMV  
283843 LYMPHOCYTIC  
16208 CHORIOMENINGITIS  
6354634 VIR?  
10155 LYMPHOCYTIC(N)CHORIOMENINGITIS(N)VIR?  
762448 RESIDUE  
103205 153  
335 RESIDUE(3N)153  
1842774 POSITION  
103205 153  
378 POSITION(3N)153  
266453 PHENYLALANINE  
103205 153  
28 PHENYLALANINE(3N)153

S4 3 (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND  
(RESIDUE (3N) 153 OR POSITION (3N) 153 OR PHENYLALANINE  
(3N) 153)

?

Display 4/3/1 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

142476299 CA: 142(26)476299z PATENT  
Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery  
INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609  
APPLICATION: US 2004993319 (20041119) \*US 2003718262 (20031120)  
PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO  
LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;  
C07K-014/005B; C12N-015/86B

- end of record -

?

Display 4/3/2 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

142476282 CA: 142(26)476282p PATENT  
Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery  
INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20050112096 A1 DATE: 20050526  
APPLICATION: US 2003718262 (20031120)  
PAGES: 25 pp. CODEN: USXXCO LANGUAGE: English CLASS: 424093200;  
A61K-048/00A; C12N-005/06B; C12N-015/867B

- end of record -

?

Display 4/3/3 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT  
New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy  
AUTHOR: MCCRAY P B; DAVIDSON B L  
PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005  
PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.: 2005-371617 (200538)  
PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120  
NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120  
LANGUAGE: English

- end of record -

?

?

S (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND (RESIDUE (3N) 260 OR POSIT  
>>>File 5 processing for VIR? stopped at VIROMAX  
>>>File 155 processing for VIR? stopped at VIRUMIN  
>>>File 73 processing for VIR? stopped at VIRUSTOMYCIN  
Processed 10 of 39 files ...  
>>>File 144 processing for VIR? stopped at VIRTUOZO  
Processing  
>>>File 50 processing for VIR? stopped at VIRUSVAKTSINOI  
Completed processing all files

6497	LCMV
283843	LYMPHOCYTIC
16208	CHORIOMENINGITIS
6354634	VIR?
10155	LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?
762448	RESIDUE
115021	260
223	RESIDUE (3N) 260
1842774	POSITION
115021	260
235	POSITION (3N) 260
266453	PHENYLALANINE
115021	260
29	PHENYLALANINE (3N) 260
S5	51 (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND (RESIDUE (3N) 260 OR POSITION (3N) 260 OR PHENYLALANINE (3N) 260)

?

S S5 AND PSEUDOTYP?

51	S5
11588	PSEUDOTYP?
S6	4 S5 AND PSEUDOTYP?

?

Display 6/3/1 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

142476299 CA: 142(26)476299z PATENT  
Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery  
INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609  
APPLICATION: US 2004993319 (20041119) \*US 2003718262 (20031120)  
PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO  
LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;  
C07K-014/005B; C12N-015/86B

- end of record -

?

Display 6/3/2 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

142476282 CA: 142(26)476282p PATENT

Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery

INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20050112096 A1 DATE: 20050526

APPLICATION: US 2003718262 (20031120)

PAGES: 25 pp. CODEN: USXXCO LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-005/06B; C12N-015/867B

- end of record -

?

Display 6/3/3 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0372996 DBR Accession No.: 2005-18702 PATENT

Transducing a nervous system cell with a transgene comprises contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene - virus vector expression in host cell for use in disease therapy and gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L; STEIN C

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L; STEIN C 2005

PATENT NUMBER: US 20050123517 PATENT DATE: 20050609 WPI ACCESSION NO.: 2005-416924 (200542)

PRIORITY APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

NATIONAL APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

LANGUAGE: English

- end of record -

?

Display 6/3/4 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT

New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005

PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.: 2005-371617 (200538)

PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

LANGUAGE: English

- end of record -

?

S S1 AND (FIV OR FELINE (N) IMMUNODEFICIENCY)

174 S1

12052 FIV  
86340 FELINE  
1115638 IMMUNODEFICIENCY  
13520 FELINE (N) IMMUNODEFICIENCY  
S7 18 S1 AND (FIV OR FELINE (N) IMMUNODEFICIENCY)

?

RD S7

&gt;&gt;&gt;Duplicate detection is not supported for File 391.

&gt;&gt;&gt;Records from unsupported files will be retained in the RD set.

...completed examining records

S8 11 RD S7 (unique items)

?

**Display 8/3/1 (Item 1 from file: 5)**

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0014569971 BIOSIS NO.: 200300524868

**TRANSGENE - SPECIFIC TOXICITY IN LENTIVIRAL VECTOR - TRANSDUCED FELINE TM  
IN VIVO**AUTHOR: Loewen N A (Reprint); Teo W (Reprint); Fautsch M P; Bahler C K;  
Johnson D H; Poeschla E M (Reprint)AUTHOR ADDRESS: Molecular Medicine, Mayo Foundation, Rochester, MN, USA\*\*  
USAJOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2003 p  
Abstract No. 1147 2003 2003

MEDIUM: cd-rom

CONFERENCE/MEETING: Annual Meeting of the Association for Research in  
Vision and Ophthalmology Fort Lauderdale, FL, USA May 04-08, 2003;  
20030504

SPONSOR: Association for Research in Vision and Ophthalmology

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

-more-

?

**Display 8/3/1 (Item 1 from file: 5)**

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

**Display 8/3/2 (Item 1 from file: 154)**

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

18202725 PMID: 15727934

The lymphocytic choriomeningitis virus envelope glycoprotein targets  
lentiviral gene transfer vector to neural progenitors in the murine brain.  
Stein Colleen S; Martins Ines; Davidson Beverly LProgram in Gene Therapy, Department of Internal Medicine, University of  
Iowa College of Medicine, Iowa City, IA 52242, USA.Molecular therapy - the journal of the American Society of Gene Therapy (United States) Mar 2005, 11 (3) p382-9, ISSN 1525-0016  
Journal Code: 100890581

Contract/Grant No.: DK54759; DK; NIDDK; NS34568; NS; NINDS  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

- end of record -

?

**Display 8/3/3 (Item 1 from file: 399)**  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

**142476299 CA: 142(26)476299z PATENT**  
Methods for producing and using in vivo pseudotyped retroviruses using  
envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for  
human gene delivery  
INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609  
APPLICATION: US 2004993319 (20041119) \*US 2003718262 (20031120)  
PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO  
LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;  
C07K-014/005B; C12N-015/86B

- end of record -

?

**Display 8/3/4 (Item 2 from file: 399)**  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

**139080197 CA: 139(6)80197w PATENT**  
Retroviral hybrid vectors pseudotyped with lymphocytic choriomeningitis  
virus and used for gene therapy  
INVENTOR(AUTHOR): Von Laer, Meike-dorothee; Beyer, Winfried  
LOCATION: Germany,  
ASSIGNEE: Heinrich-Pette-Institute  
PATENT: United States ; US 6589763 B1 DATE: 20030708  
APPLICATION: US 718096 (20001122) \*DE 19856463 (19981126) \*US 309572  
(19990511) \*EP 99250415 (19991125)  
PAGES: 65 pp., Cont.-in-part of U.S. Ser. No. 309,572. CODEN: USXXAM  
LANGUAGE: English CLASS: 435069100; C12P-021/06A; C12N-015/63B;  
C12N-015/00B; C07H-021/04B; C07K-001/00B

- end of record -

?

**Display 8/3/5 (Item 3 from file: 399)**  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2005 American Chemical Society. All rts. reserv.

**133027363 CA: 133(3)27363x PATENT**  
Pseudotyping retroviral vectors by replacing the envelope glycoprotein  
with the lymphocytic choriomeningitis virus glycoprotein to increase host  
cell range  
INVENTOR(AUTHOR): Von Laer, Meike-dorothee  
LOCATION: Germany,  
ASSIGNEE: Heinrich-Pette-Institut

PATENT: European Pat. Appl. ; EP 1006196 A2 DATE: 20000607  
APPLICATION: EP 99250415 (19991125) \*DE 19856463 (19981126)  
PAGES: 69 pp. CODEN: EPXXDW LANGUAGE: German CLASS: C12N-015/867A;  
C12N-005/10B; C12N-007/01B; A61K-048/00B; C07K-014/08B; C12N-015/40B  
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;  
SE; MC; PT; IE; SI; LT; LV; FI; RO

- end of record -

?

**Display 8/3/6 (Item 1 from file: 34)**  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2005 Inst for Sci Info. All rts. reserv.

13082956 Genuine Article#: 833DM No. References: 0  
**Title: Improved apical airway epithelia targeting properties of FIV vector pseudotyped with envelopes from LCMV**  
Author(s): Dylla DE; Hickey MA; Michele DE; Davidson BL; Campbell KP;  
McCray PB  
Corporate Source: Univ Iowa, Program Gene Therapy, Iowa City//IA/  
Journal: MOLECULAR THERAPY, 2004, V9, 1 (MAY), PS186-S186  
ISSN: 1525-0016 Publication date: 20040500  
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN  
DIEGO, CA 92101-4495 USA  
Language: English Document Type: MEETING ABSTRACT

- end of record -

?

**Display 8/3/7 (Item 1 from file: 73)**  
DIALOG(R)File 73:EMBASE  
(c) 2005 Elsevier Science B.V. All rts. reserv.

11857703 EMBASE No: 2002429700  
**No false start for novel pseudotyped vectors**  
Sanders D.A.  
D.A. Sanders, Department of Biological Sciences, Purdue University, West  
Lafayette, IN 47907 United States  
AUTHOR EMAIL: retrovir@bragg.bio.purdue.edu  
Current Opinion in Biotechnology ( CURR. OPIN. BIOTECHNOL. ) (United  
Kingdom) 01 OCT 2002, 13/5 (437-442)  
CODEN: CUOBE ISSN: 0958-1669  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 41

- end of record -

?

**Display 8/3/8 (Item 1 from file: 266)**  
DIALOG(R)File 266:FEDRIP  
Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00624119  
IDENTIFYING NO.: 2P01HL051670-11 0005 AGENCY CODE: CRISP  
**Targeting Entry in Epithelia with ICMV-FIV**  
PRINCIPAL INVESTIGATOR: MCCRAY, PAUL B, JR  
ADDRESS: PAUL-MCCRAY@UIOWA.EDU UNIVERSITY OF IOWA 616 MEDICAL RESEARCH  
CENTER IOWA CITY, IA 52242  
PERFORMING ORG.: UNIVERSITY OF IOWA, IOWA CITY, IOWA

SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE  
DATES: 2009/01/97 TO 2003/31/09 FY : 2004

- end of record -

?

Display 8/3/9 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0372996 DBR Accession No.: 2005-18702 PATENT

Transducing a nervous system cell with a transgene comprises contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene - virus vector expression in host cell for use in disease therapy and gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L; STEIN C

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L; STEIN C 2005

PATENT NUMBER: US 20050123517 PATENT DATE: 20050609 WPI ACCESSION NO.: 2005-416924 (200542)

PRIORITY APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

NATIONAL APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

LANGUAGE: English

- end of record -

?

Display 8/3/10 (Item 2 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT

New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005

PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.: 2005-371617 (200538)

PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

LANGUAGE: English

- end of record -

?

Display 8/3/11 (Item 3 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0329671 DBR Accession No.: 2004-01963 PATENT

New chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a heterologous amino acid sequence, useful for inducing an immune response against Ebola virus, bacteria, or fungi - involving vector-mediated gene transfer and expression in host cell for use in therapy

AUTHOR: WILSON J M; MEDINA M F C; KOBINGER G

PATENT ASSIGNEE: UNIV PENNSYLVANIA 2003  
PATENT NUMBER: WO 200392582 PATENT DATE: 20031113 WPI ACCESSION NO.:  
2004-011795 (200401)  
PRIORITY APPLIC. NO.: US 427752 APPLIC. DATE: 20021120  
NATIONAL APPLIC. NO.: WO 2003US11494 APPLIC. DATE: 20030428  
LANGUAGE: English

- end of record -

?

Ref	Items	Index-term
E1	2	AU=MCCRAY, PATRICK DALE
E2	3	AU=MCCRAY, PAUL
E3	2	*AU=MCCRAY, PAUL B
E4	10	AU=MCCRAY, PAUL B JR
E5	9	AU=MCCRAY, PAUL B.
E6	2	AU=MCCRAY, PAUL B. JR.
E7	96	AU=MCCRAY, PAUL B., JR.
E8	7	AU=MCCRAY, PAUL B.,JR
E9	4	AU=MCCRAY, PAUL B, JR
E10	1	AU=MCCRAY, PAUL M., JR.
E11	2	AU=MCCRAY, PAULA
E12	5	AU=MCCRAY, PB

Enter P or PAGE for more

?

Ref	Items	Index-term
E1	4	AU=MCCRAY P.B.
E2	76	AU=MCCRAY P.B. JR.
E3	6	*AU=MCCRAY PAUL
E4	85	AU=MCCRAY PAUL B
E5	136	AU=MCCRAY PAUL B JR
E6	4	AU=MCCRAY PAUL M
E7	140	AU=MCCRAY PB
E8	1	AU=MCCRAY PC
E9	3	AU=MCCRAY PD
E10	2	AU=MCCRAY PERCY
E11	2	AU=MCCRAY PL
E12	2	AU=MCCRAY PM

Enter P or PAGE for more

?

Ref	Items	Index-term
E1	1	AU=DAVIDSON, BEVERELY L.
E2	1	AU=DAVIDSON, BEVERLEY L.
E3	7	*AU=DAVIDSON, BEVERLY
E4	22	AU=DAVIDSON, BEVERLY L
E5	186	AU=DAVIDSON, BEVERLY L.
E6	4	AU=DAVIDSON, BEVERLY LONG
E7	1	AU=DAVIDSON, BH
E8	4	AU=DAVIDSON, BILL
E9	1	AU=DAVIDSON, BILLY
E10	1	AU=DAVIDSON, BILLY H.
E11	1	AU=DAVIDSON, BIRGITTA
E12	7	AU=DAVIDSON, BJ

Enter P or PAGE for more

?

Ref	Items	Index-term
E1	3	AU=DAVIDSON BETH TOWERY
E2	8	AU=DAVIDSON BEVERLEY L
E3	31	*AU=DAVIDSON BEVERLY
E4	371	AU=DAVIDSON BEVERLY L
E5	2	AU=DAVIDSON BG
E6	3	AU=DAVIDSON BH
E7	1	AU=DAVIDSON BI
E8	2	AU=DAVIDSON BINYAMIN
E9	68	AU=DAVIDSON BJ
E10	2	AU=DAVIDSON BK
E11	5	AU=DAVIDSON BKS
E12	329	AU=DAVIDSON BL

Enter P or PAGE for more

?